Information for manufacturers on the regulations that apply to prosthetic, orthotic and ophthalmic devices.
Similar Posts
Decision: Advertising Investigations: October 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Cancel a medicine’s marketing authorisation or other licence
Cancel a marketing authorisation, traditional herbal registration or parallel import product licence or withdraw a pending submission.
Field Safety Notices: 19 to 23 January 2026
List of Field Safety Notices from 19 to 23 January 2026.
Class 2 Medicines Recall: Inhixa 12,000IU (120mg)/0.8mL solution for injection, Maxearn Limited, EL(25)A/27
Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.
Sir David Spiegelhalter: Regulation in an age of personalised medicine
The internationally renowned expert in the calculation and communication of risk and statistics, Sir David Spiegelhalter, discusses the concept of a ‘preference zone’ to frame the demands of safety, efficacy and choice in the era of personalised medicine.
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): updated safety and educational materials to support patient discussion on reproductive risks
Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They also include previous updates to product information on the risk of low birth weight in children exposed to valproate during pregnancy.